Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Morphic Holding, Inc.    MORF

MORPHIC HOLDING, INC.

(MORF)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/24/2020 11/25/2020 11/27/2020 11/30/2020 12/01/2020 Date
31.33(c) 32.57(c) 32.08(c) 31.37(c) 31(c) Last
170 863 107 622 41 384 163 352 48 996 Volume
+1.59% +3.96% -1.50% -2.21% -1.18% Change
More quotes
Financials (USD)
Sales 2020 45,6 M - -
Net income 2020 -44,8 M - -
Net Debt 2020 - - -
P/E ratio 2020 -21,5x
Yield 2020 -
Sales 2021 35,4 M - -
Net income 2021 -64,3 M - -
Net Debt 2021 - - -
P/E ratio 2021 -16,0x
Yield 2021 -
Capitalization 965 M 965 M -
Capi. / Sales 2020 21,1x
Capi. / Sales 2021 27,3x
Nbr of Employees 87
Free-Float 58,8%
More Financials
Company
Morphic Holding, Inc is a biopharmaceutical company. The Company is engaged in discovering and developing a pipeline of potentially first-in-class oral small-molecule integrin therapeutics. Integrins are a target class with multiple approved injectable blockbuster drugs for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. The Company is... 
Sector
Pharmaceuticals
Calendar
03/04Earnings Release
More about the company
Notations Surperformance© of Morphic Holding, Inc.
Trading Rating : Investor Rating :
More Ratings
All news about MORPHIC HOLDING, INC.
11/18MORPHIC : Therapeutic to present at the jefferies virtual london healthcare conf..
AQ
11/17MORPHIC : Therapeutic to Present at the Jefferies Virtual London Healthcare Conf..
AQ
11/17Morphic Therapeutic to Present at the Jefferies Virtual London Healthcare Con..
GL
11/09MORPHIC : Management's Discussion and Analysis of Financial Condition and Result..
AQ
11/09MORPHIC HOLDING, INC. : Results of Operations and Financial Condition, Regulatio..
AQ
11/09MORPHIC : Announces Corporate Highlights and Third Quarter 2020 Financial Result..
AQ
11/09Morphic Announces Corporate Highlights and Third Quarter 2020 Financial Resul..
GL
10/13MORPHIC : Announces presentation of new data supporting development of morf-057 ..
AQ
10/12MORPHIC : Announces Presentation of New Data Supporting Development of MORF-057 ..
AQ
10/12Morphic Announces Presentation of New Data Supporting Development of MORF-057..
GL
10/12MORPHIC : October 2020 UEG Presentation
PU
09/24MORPHIC : Therapeutic announces first healthy volunteers dosed in phase 1 clinic..
AQ
09/23MORPHIC HOLDING, INC. : Other Events, Financial Statements and Exhibits (form 8-..
AQ
09/23MORPHIC : Therapeutic Announces First Healthy Volunteers Dosed in Phase 1 Clinic..
AQ
09/23Morphic Therapeutic Announces First Healthy Volunteers Dosed in Phase 1 Clini..
GL
More news
News in other languages on MORPHIC HOLDING, INC.

- No features available -

More news
Chart MORPHIC HOLDING, INC.
Duration : Period :
Morphic Holding, Inc. Technical Analysis Chart | MORF | US61775R1059 | MarketScreener
Technical analysis trends MORPHIC HOLDING, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 37,25 $
Last Close Price 31,00 $
Spread / Highest target 29,0%
Spread / Average Target 20,2%
Spread / Lowest Target 9,68%
EPS Revisions
Managers
NameTitle
Praveen P. Tipirneni President, Chief Executive Officer & Director
Gustav A. Christensen Chairman
Marc Schegerin Chief Operating & Financial Officer
Bruce N. Rogers Chief Scientific Officer
Peter G. Linde Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
MORPHIC HOLDING, INC.82.81%976
JOHNSON & JOHNSON-0.82%380 876
ROCHE HOLDING AG-4.76%282 467
PFIZER, INC.3.21%212 942
NOVARTIS AG-10.48%206 479
MERCK & CO., INC.-11.61%203 389